SCHEDULE 13G/A: BB Biotech AG Exits Significant Stake in MacroGenics Inc.
Beneficial Ownership Change
BB Biotech AG and its subsidiary Biotech Target N.V. have filed an exit Schedule 13G, indicating they no longer beneficially own 5% or more of MacroGenics Inc.'s common stock.
Summary
- BB Biotech AG and its wholly-owned subsidiary, Biotech Target N.V., have filed Amendment No. 11 to their Schedule 13G for MacroGenics Inc.
- This filing serves as an 'exit filing' because the reporting persons now own less than five percent (5%) of the common shares of MacroGenics Inc.
- As of the filing, BB Biotech AG and Biotech Target N.V. beneficially own 0 shares, representing 0% of the common stock of MacroGenics Inc.
- The event requiring this filing occurred on June 1, 2025.
Sentiment
Score: 5
Explanation: This is a purely factual regulatory filing about a change in beneficial ownership, not a performance report or strategic announcement from the company. The document itself is neutral in tone and content regarding MacroGenics Inc.'s operations or financial health.
Future Outlook
NA
Industry Context
This filing reflects a change in institutional investor holdings within the biotechnology sector, where significant stake changes by major investment firms like BB Biotech AG can be closely watched by market participants.
Related Party Transactions
- Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG, and they are filing this statement jointly as related reporting persons.
Stakeholder Impact
- Shareholders: May interpret the exit of a significant institutional investor as a signal, potentially influencing market perception or trading activity for MacroGenics Inc. shares.
Key Dates
| Date | Description |
|---|---|
| 12/29/2016 | Date of previously filed Schedule 13G where Exhibit A (Agreement between BB Biotech AG and Biotech Target N.V.) was first filed. |
| 06/01/2025 | Date of event which required the filing of this statement, indicating the reporting persons' beneficial ownership dropped below 5%. |
| 06/13/2025 | Date of filing of Amendment No. 11 to Schedule 13G. |
Keywords
MacroGenics Inc, BB Biotech AG, Biotech Target N.V., Schedule 13G, Beneficial Ownership, Common Stock, Exit Filing, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.